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Our work with synthetic prion protein (PrP) peptides
stemmed from previous ¢ndings that (i) the amyloid protein
from patients with Gerstmann^Stra«ussler^Scheinker (GSS)
disease (a genetic form of prion disease) is a PrP fragment
whose N-terminus is located within residues 58^90 (i.e. the
octapeptide repeat region) and C-terminus corresponds to res-
idue V150 [1,2], and (ii) the accumulation of this fragment in
the brain is accompanied by neuronal degeneration and glial
activation [3]. Since amyloid proteins have a high content of
L-sheet secondary structure [4] ^ a feature which distinguishes
the normal PrP (PrPC) from disease-speci¢c PrP isoforms
(PrPSc) [5] ^ we synthesised a series of peptides corresponding
to consecutive segments of the GSS amyloid subunit to inves-
tigate which PrP sequence is central to conformational change
and amyloid formation, and whether accumulation of abnor-
mal PrP peptides is responsible for nerve and glial cell changes
found in prion diseases. These studies showed that, unlike
other PrP sequences, the peptide homologous to residues
106^126 (PrP106^126) is sparingly soluble in aqueous solu-
tions, has a high propensity to adopt L-sheet secondary struc-
ture and form amyloid ¢brils, is neurotoxic, and induces hy-
pertrophy and proliferation of astrocytes [6^9]. Drs D. Brown
and H. Kretzschmar extended these studies and showed that
PrP106^126 activates microglial cells which increases their
oxygen radical production, becoming an important mediator
of neurotoxicity [10]. It is noteworthy that these and many
other e¡ects (e.g. interaction of the peptide with cell mem-
branes, changes of intracellular calcium levels) have been ob-
served with the protease-resistant core of PrPSc [11^14] sug-
gesting that the sequence comprising residues 106^126 plays a
major role in the conformational conversion of PrPC into
PrPSc as well as in the pathogenesis of brain changes occur-
ring in prion diseases.
Following our original report [6], numerous other groups
have con¢rmed the neurotoxicity of PrP106^126 in primary
cultures and cell lines (see [15] for references). PrP106^126 has
also been used to evaluate the relationship between conforma-
tional state and biological activity [16] and to test neuropro-
tective drugs [17,18]. In these studies, a scrambled sequence of
PrP106^126 as well as other PrP peptides and chemically un-
related peptides were analysed to provide adequate control
conditions, as mentioned by D. Brown in the comment on
Kunz’s article [19]. The peptides were obtained from several
di¡erent sources, both industrial (e.g. Bachem, Seven Biotech
Ltd) and academic (e.g. University of Go«ttingen, Edinburgh,
Madrid), and the possibility that a chemical contaminant with
similar properties was systematically and exclusively associ-
ated with PrP106^126 seems highly improbable. If, in the un-
likely case, this event could have occurred, then we believe
that such a contaminant should be identi¢ed. This is an im-
portant control experiment that has been omitted by Kunz
and co-workers [15] but, in our opinion, is essential to sub-
stantiate their ¢ndings.
It is not unusual to ¢nd variations in biological activity of
synthetic amyloid peptides between di¡erent batches inde-
pendent of their sequence. A prime example is the amyloid-
L (AL) of Alzheimer’s disease. Following the ¢rst demonstra-
tion that AL peptides are neurotoxic in vitro [20], contrasting
results were obtained by other groups, and an entire issue of
Neurobiology of Aging (Vol. 13, No. 5, 1992) was dedicated
to this debate. Today, the toxicity of AL peptides is widely
accepted, although it is common experience to ¢nd batches
that do not exhibit neurotoxicity even after peptide aging.
One possible explanation for this discrepancy is that di¡erent
lots of the same peptide can adopt di¡erent conformations
and have di¡erent aggregation properties, which may be im-
portant determinants of neurotoxicity [21]. However, the rela-
tionship between these factors is complex and only partially
understood. Neurotoxicity might be due to metastable proto-
¢brillar intermediates rather than ^ or in addition to ^ mature
amyloid ¢brils and an excess of ¢brillogenic ability might in-
deed lower the neurotoxic activity of a peptide [22,23]. Con-
sequently, the interpretation of results from cell culture stud-
ies requires extensive characterisation and knowledge of the
chemicophysical properties of individual peptides. When such
information is limited, it is inappropriate to derive general
conclusions, particularly when a peptide was obtained from
a single source. This is one of the main problems in the study
by Kunz and co-workers.
A surprising fact is that Dr Kunz was unable to observe
neurotoxicity using a PrP106^126 peptide obtained by Dr
Kretzschmar [24] and, on the other hand, Dr Brown found
some neurotoxicity using ‘un¢ltered’ PrP106^126 provided by
Kunz [19]. These results suggest di¡erences in methodologies.
However, as previously mentioned, it is important to remem-
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ber that the neurotoxicity of PrP106^126 has been successfully
replicated in many laboratories throughout the world. Since
Dr Kunz and co-authors are open to suggestions, we would
advise them to test several commercially available PrP pep-
tides and make the results public.
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